Procter & Gamble Health Limited - Asset Resilience Ratio
Procter & Gamble Health Limited (PGHL) has an Asset Resilience Ratio of 33.01% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PGHL working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how Procter & Gamble Health Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Procter & Gamble Health Limited asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Procter & Gamble Health Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Procter & Gamble Health Limited (PGHL) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs2.79 Billion | 31.23% |
| Short-term Investments | Rs159.40 Million | 1.78% |
| Total Liquid Assets | Rs2.95 Billion | 33.01% |
Asset Resilience Insights
- Very High Liquidity: Procter & Gamble Health Limited maintains exceptional liquid asset reserves at 33.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Procter & Gamble Health Limited Industry Peers by Asset Resilience Ratio
Compare Procter & Gamble Health Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Procter & Gamble Health Limited (2003–2024)
The table below shows the annual Asset Resilience Ratio data for Procter & Gamble Health Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.33% | Rs1.14 Billion ≈ $12.31 Million |
Rs7.94 Billion ≈ $85.89 Million |
-6.95pp |
| 2023-12-31 | 21.27% | Rs1.69 Billion ≈ $18.28 Million |
Rs7.94 Billion ≈ $85.91 Million |
-11.18pp |
| 2022-12-31 | 32.45% | Rs3.57 Billion ≈ $38.65 Million |
Rs11.01 Billion ≈ $119.09 Million |
-5.27pp |
| 2021-12-31 | 37.72% | Rs3.37 Billion ≈ $36.46 Million |
Rs8.94 Billion ≈ $96.65 Million |
-5.76pp |
| 2020-12-31 | 43.48% | Rs4.29 Billion ≈ $46.37 Million |
Rs9.86 Billion ≈ $106.65 Million |
-7.40pp |
| 2019-12-31 | 50.88% | Rs5.99 Billion ≈ $64.73 Million |
Rs11.76 Billion ≈ $127.22 Million |
+18.21pp |
| 2018-12-31 | 32.67% | Rs5.75 Billion ≈ $62.17 Million |
Rs17.59 Billion ≈ $190.28 Million |
+25.61pp |
| 2017-12-31 | 7.06% | Rs699.70 Million ≈ $7.57 Million |
Rs9.91 Billion ≈ $107.20 Million |
+3.91pp |
| 2016-12-31 | 3.15% | Rs277.80 Million ≈ $3.00 Million |
Rs8.83 Billion ≈ $95.47 Million |
-2.25pp |
| 2015-12-31 | 5.39% | Rs422.80 Million ≈ $4.57 Million |
Rs7.84 Billion ≈ $84.78 Million |
+2.02pp |
| 2014-12-31 | 3.37% | Rs238.70 Million ≈ $2.58 Million |
Rs7.08 Billion ≈ $76.59 Million |
-0.37pp |
| 2013-12-31 | 3.74% | Rs242.90 Million ≈ $2.63 Million |
Rs6.49 Billion ≈ $70.14 Million |
-0.23pp |
| 2012-12-31 | 3.98% | Rs236.40 Million ≈ $2.56 Million |
Rs5.94 Billion ≈ $64.27 Million |
-17.82pp |
| 2006-12-31 | 21.80% | Rs1.04 Billion ≈ $11.30 Million |
Rs4.79 Billion ≈ $51.84 Million |
+0.55pp |
| 2005-12-31 | 21.25% | Rs823.10 Million ≈ $8.90 Million |
Rs3.87 Billion ≈ $41.90 Million |
+7.70pp |
| 2004-12-31 | 13.54% | Rs442.80 Million ≈ $4.79 Million |
Rs3.27 Billion ≈ $35.36 Million |
+2.75pp |
| 2003-12-31 | 10.79% | Rs300.00 Million ≈ $3.24 Million |
Rs2.78 Billion ≈ $30.07 Million |
-- |
About Procter & Gamble Health Limited
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter … Read more